Plain-English translation of NCT06323369 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study compares two different treatment approaches for head and neck squamous cell carcinoma (a type of cancer in the head or neck region). One group receives Tislelizumab, an immunotherapy medication combined with chemotherapy before surgery, while the other group goes straight to surgery. The goal is to see which approach works better at preventing cancer from coming back.
Doctors want to understand whether giving this medication along with chemotherapy before surgery can help prevent cancer recurrence better than surgery alone, especially for patients whose cancer hasn't spread to lymph nodes yet.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to one of two groups. One group receives the medication plus chemotherapy as three treatment cycles before surgery, while the other group has surgery right away. After surgery, depending on whether cancer is found in your lymph nodes, you may receive additional treatment. Throughout the trial, you'll have multiple clinic visits for blood tests, scans, and check-ups to monitor how you're doing and whether the treatment is working.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China